Subscribe to NRx Newsletter

Updates from the CEO

CEO Update: History of Aviptadil

I received a very interesting question the other day regarding the history of aviptadil and any regulatory milestones associated with it as a medicine. Below, I outline a brief history of aviptadil and why we believe it may offer patients suffering respiratory distress the opportunity to regain health and get back home to their families. […]

CEO Update: Ongoing Communications with the US Food and Drug Administration

NRx Pharmaceuticals continues to receive many requests for updates on the status of the US Food and Drug Administration’s (FDA) review of NRx’s application for Emergency Use Authorization (EUA) of ZYESAMI™ (aviptadil), to treat patients suffering from Critical COVID-19 with respiratory failure. On September 3, 2021, NRx received a request for additional clinical information from […]

CEO Update: Right to Try

A year ago, at FDA’s request, NRx began a compassionate care (Expanded Access) program to make aviptadil more available to patients in need.  We have reported our experience in nearly 350 patients, and numerous patients and families have shared their stories in various public forums. The compassionate care program was, of necessity, limited to a […]

CEO Update: Aviptadil & patents for VIP

Every day at NRx we get a variety of questions about our science, business, and other aspects of our work. This CEO Update concerns aviptadil and questions about patents for this peptide. Q: What’s the difference between aviptadil and VIP?A:  VIP stands for vasoactive intestinal peptide.  It is made in specialized cells like insulin. Aviptadil is […]

CEO Update: July 21, 2021 Panel Discussion hosted by the Disease Prevention & Control Summit

On Wednesday, July 21, 2021, Prof Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals, participated in a panel discussion hosted by the Disease Prevention & Control Summit. The specific panel discussion focused on small molecules and repurposed medicines for COVID-19 treatment. Jonathan received several questions from those watching the panel discussion. Below, are […]